Beckman Daniella
Chief Financial Officer
Beckman Daniella has filed 1 SEC Form 4 filing (3 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Feb 4, 2026.
On the most recent filing, Beckman Daniella is listed as Chief Financial Officer at Tango Therapeutics, Inc. Inside the rolling window, Beckman Daniella reported no open-market purchases and 1 open-market sale totaling $127K in TNGX.
Companies traded
Other insiders at TNGX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$127K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Beckman Daniella made?
Beckman Daniella has filed 1 SEC Form 4 filing (3 transaction rows) across 1 company since 2026.
Which companies does Beckman Daniella trade?
Beckman Daniella has filed SEC Form 4 disclosures for 1 company, including TNGX.
When was Beckman Daniella's most recent SEC Form 4 filing?
Beckman Daniella's most recent SEC Form 4 filing on Tracefour is dated Feb 4, 2026.
What is Beckman Daniella's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Beckman Daniella is listed as Chief Financial Officer.
What is Beckman Daniella's total buy and sell value in the current window?
Inside the rolling retention window, Beckman Daniella bought $0 and sold $127K based on SEC Form 4 filings.
What was Beckman Daniella's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,317 TNGX shares on 2026-02-03, worth $127K, per SEC Form 4 filings.